MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
ITEM 7.01

REGULATION FD DISCLOSURE.

On January 4, 2019, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company had entered into discussions and letter of intent with Oncotelic, Inc. on January 3, 2019, regarding exploration of a potential reverse merger transaction between the two companies. The two companies signed a non-binding letter of intent in connection with the discussions.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

(d)Exhibits.

MABVAX THERAPEUTICS HOLDINGS, INC. Exhibit
EX-99.1 2 mbvx_ex991.htm EXHIBIT 99.1 Blueprint   Exhibit 99.1 MabVax Therapeutics and Oncotelic Enter into Merger Discussions   Divestiture of Selected MabVax Assets Managed by Objective Capital Will Continue   SAN DIEGO (January 4,…
To view the full exhibit click here